

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**MicroTech Medical (Hangzhou) Co., Ltd.**  
**微泰醫療器械(杭州)股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2235)**

**POLL RESULTS OF  
THE 2022 FIRST EXTRAORDINARY GENERAL MEETING  
THE 2022 SECOND CLASS MEETING OF HOLDERS OF H SHARES  
THE 2022 SECOND CLASS MEETING OF HOLDERS OF  
DOMESTIC UNLISTED SHARES  
AND  
CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND  
CHANGE IN COMPOSITION OF BOARD COMMITTEE**

Reference is made to the circular of MicroTech Medical (Hangzhou) Co., Ltd (the “**Company**”) dated November 21, 2022 in relation to the EGM, Class Meeting of H Shareholders and Class Meeting of Domestic Unlisted Shareholders (the “**Circular**”). Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The Board hereby announces that (i) the EGM, (ii) the Class Meeting of H Shareholders and (iii) the Class Meeting of Domestic Unlisted Shareholders (collectively, the “**Meetings**”) were held at Business Conference Room, 3rd Floor, MicroTech Medical Administration Building, No. 108 Liuze Street, Cangqian Street, Yuhang District, Hangzhou, Zhejiang, China on Wednesday, December 7, 2022. All proposed resolutions (the “**Resolutions**”) put forward at the Meetings were duly passed by the Shareholders by the way of poll.

As at the date of the Meetings, the total number of Shares in issue was 425,742,600 (including 170,322,929 H Shares and 255,419,671 Domestic Unlisted Shares). To the best knowledge, information and belief of Director, save for that Dr. Zheng Pan, Hangzhou Yantai and Hangzhou Hengtai, collectively holding 41,437,919 H Shares and 82,009,537 Domestic Unlisted Shares, shall abstain from voting in the resolution numbered 12 at the EGM, (i) no Shareholders were required under the Hong Kong Listed Rules to abstain from voting on any of the Resolutions; (2) there were no Shares entitling the holders thereof to attend the Meetings and abstain from voting in favor of any of the Resolutions under Rule 13.40 of the Hong Kong Listing Rules; and (iii) no Shareholders have indicated in the Circular that they intend to vote against or to abstain from voting on any of the Resolutions.

Dr. Zheng Pan, Chairman of the Company, acted as the chairman of the Meetings and presided over the Meetings. Tricor Investor Services Limited, the Company’s H share registrar, acted as the scrutineer for the vote-taking at the Meetings. The convening of the Meetings is in compliance with the Company Law of the People’s Republic of China and the Articles of Association.

Directors, Dr. Zheng Pan, Dr. Yu Fei, Dr. Shi Yonghui and Ms. Liu Xiu, attended the Meetings in person; and Mr. Hu Xubo, Ms. Gao Yun, Dr. Li Lihua, Mr. Ho Kin Cheong Kelvin, Ms. Wang Chunfeng, Ms. Gao Jian (whose resignation took effect from the conclusion of the EGM) and Dr. Cheng Hua (whose appointment took effect from the conclusion of the EGM) attended the Meetings by electronics means.

## **I. CONVENING OF THE MEETINGS**

### **(I) EGM**

For the resolution numbered 12, Dr. Zheng Pan, Hangzhou Yantai and Hangzhou Hengtai, collectively holding 41,437,919 H Shares and 82,009,537 Domestic Unlisted Shares, were required to, and had, abstained from voting on such resolution at the EGM to approve the confirmation of the Company's related-party transactions in the past three years. The total Shares entitling the holders to attend and vote on the resolution numbered 12 and other resolutions proposed at the EGM were 302,295,144 and 425,742,600 respectively. The total number of Shares with voting right, on the resolution numbered 12 and other resolutions, represented by the Shareholders attending the EGM in person or by proxy was 270,859,380 and 393,867,536 representing 89.60% and 92.51% of the total number of Share with voting rights, respectively.

### **(II) Class Meeting of H Shareholders**

The total number of H Shares entitling the holders to attend and vote on the resolutions at the Class Meeting of Holders of H Shares was 170,322,929. H Shareholders and proxies of H Shareholders who attended the Class Meeting of H Shareholders held a total of 138,871,473 H Shares with voting rights, representing approximately 81.53% of the total number of H Shares with voting rights.

### **(III) Class Meeting of Domestic Unlisted Shareholders**

The total number of Domestic Unlisted Shares entitling the holders to attend and vote on the resolutions at the Class Meeting of Domestic Unlisted Shareholders was 255,419,671. Domestic Unlisted Shareholders and proxies of Domestic Unlisted Shareholders who attended the Class Meeting of Domestic Unlisted Shareholders held a total of 253,625,563 Domestic Unlisted Shares with voting rights, representing approximately 99.30% of the total number of Unlisted Shares with voting rights.

## II. POLL RESULTS OF THE MEETINGS

### (I) Poll Results of the EGM

The poll results in respect of the resolutions proposed at the EGM were as follows:

Special Resolutions		Number of valid votes and percentage of total votes (%)			Total votes
		For	Against	Abstain	
1.	To consider and approve the proposed A Share Offering: (a) Place of listing; (b) Class of securities to be issued; (c) Nominal value of shares; (d) Target subscribers; (e) Schedule of the offering; (f) Method of offering; (g) Offering size; (h) Pricing methodology; (i) Implementation of strategic placing upon issue; (j) Method of underwriting; and (k) Validity period of resolutions in relation to the Offering.	386,096,419 (98.03%)	6,304,210 (1.60%)	1,466,907 (0.37%)	393,867,536
2.	To consider and approve the authorization to the Company's board and its authorized persons to deal with specific matters relating to the proposed A Share Offering with full discretion;	384,624,066 (98.02%)	6,304,210 (1.61%)	1,466,907 (0.37%)	392,395,183
3.	To consider and approve the investment projects financed by proceeds from the proposed A Share Offering and the relevant feasibility analysis;	386,096,419 (98.03%)	6,304,210 (1.60%)	1,466,907 (0.37%)	393,867,536
4.	To consider and approve the proposal for distribution of accumulated profits retained or plan for undertaking of unrecovered losses incurred cumulatively prior to the A Share Offering;	384,624,066 (98.02%)	6,304,210 (1.61%)	1,466,907 (0.37%)	392,395,183

Special Resolutions		Number of valid votes and percentage of total votes (%)			Total votes
		For	Against	Abstain	
5.	To consider and approve the plan for stabilizing A Share price within three years after the proposed A Share Offering as set out in Appendix I to the Circular;	386,096,419 (98.03%)	6,304,210 (1.60%)	1,466,907 (0.37%)	393,867,536
6.	To consider and approve the dilution of immediate return as a result of the A Share Offering and recovery measures;	386,096,419 (98.03%)	6,304,210 (1.60%)	1,466,907 (0.37%)	393,867,536
7.	To consider and approve the plan for dividend distribution to Shareholders in three years after the proposed A Share Offering as set out in Appendix II to the Circular;	386,096,419 (98.03%)	6,304,210 (1.60%)	1,466,907 (0.37%)	393,867,536
8.	To consider and approve the undertakings and restraining measures in respect of the proposed A Share Offering as set out in Appendix III to the Circular;	386,096,419 (98.03%)	6,304,210 (1.60%)	1,466,907 (0.37%)	393,867,536
9.	To consider and approve (i) the Proposed Amendments to the Current Articles of Association, details of which are set out in Appendix IV-A to the Circular; and (ii) the adoption of the Amended Articles of Association which contains all the Proposed Amendments to the Current Articles of Association (a copy of which has been proposed at this EGM and marked "A" and initialed by the chairman of the EGM) in substitution for and to the exclusion of the current articles of association of the Company with immediate effect;	386,096,419 (98.03%)	6,304,210 (1.60%)	1,466,907 (0.37%)	393,867,536

Special Resolutions		Number of valid votes and percentage of total votes (%)			Total votes
		For	Against	Abstain	
10.	To consider and approve (i) the Proposed Amendments to the Articles of Association for the A Share Offering, details of which are set out in Appendix IVB to the Circular; and (ii) the adoption of the Amended Articles of Association which contains all the Proposed Amendments to the Articles of Association for the A Share Offering (a copy of which has been proposed at the EGM and marked “B” and initialed by the chairman of the EGM) in substitution for and to the exclusion of the current articles of association of the Company with immediate effect.	386,096,419 (98.03%)	6,304,210 (1.60%)	1,466,907 (0.37%)	393,867,536

As more than two-thirds of the votes from the Shareholders (including their proxies) attending the EGM, with voting rights, were cast in favor of the resolutions numbered 1 to 10 above, resolutions numbered 1 to 10 were duly passed.

Ordinary Resolutions		Number of valid votes and percentage of total votes (%)			Total votes
		For	Against	Abstain	
11.	To consider and approve the engagement of intermediaries;	386,096,419 (98.03%)	6,304,210 (1.60%)	1,466,907 (0.37%)	393,867,536
12.	To consider and approve the confirmation of the Company’s related-party transactions in the past three years;	263,088,263 (97.13%)	6,304,210 (2.33%)	1,466,907 (0.54%)	270,859,380
13.	To consider and approve the report on the use of proceeds from the previous fundraising activity as set out in Appendix V to the Circular;	386,096,419 (98.03%)	6,304,210 (1.60%)	1,466,907 (0.37%)	393,867,536
14.	To consider and approve the amendment or formulation of internal management policies of the Company as set out in Appendix VI to Appendix XV to the Circular;	386,096,419 (98.03%)	6,304,210 (1.60%)	1,466,907 (0.37%)	393,867,536

Ordinary Resolutions		Number of valid votes and percentage of total votes (%)			Total votes
		For	Against	Abstain	
15.	To consider and approve the appointment of Dr. Cheng Hua as an independent non-executive director of the Company.	392,400,629 (99.63%)	0 (0.00%)	1,466,907 (0.37%)	393,867,536

As more than half of the votes from the Shareholders (including their proxies) attending the EGM, with voting rights, were cast in favor of the resolutions numbered 11 to 15 above, resolutions numbered 11 to 15 were duly passed.

## (II) Poll Results of the Class Meeting of H Shareholders

The poll results in respect of the resolutions proposed at the Class Meeting of H Shareholders were as follows:

Special Resolutions		Number of valid votes and percentage of total votes (%)			Total votes
		For	Against	Abstain	
1.	To consider and approve the proposed A Share Offering: (a) Place of listing; (b) Class of securities to be issued; (c) Nominal value of shares; (d) Target subscribers; (e) Schedule of the offering; (f) Method of offering; (g) Offering size; (h) Pricing methodology; (i) Implementation of strategic placing upon issue; (j) Method of underwriting; and (k) Validity period of resolutions in relation to the Offering.	131,100,356 (94.40%)	6,304,210 (4.54%)	1,466,907 (1.06%)	138,871,473
2.	To consider and approve the authorization to the Company's board and its authorized persons to deal with specific matters relating to the proposed A Share Offering with full discretion;	131,100,356 (94.40%)	6,304,210 (4.54%)	1,466,907 (1.06%)	138,871,473

Special Resolutions		Number of valid votes and percentage of total votes (%)			Total votes
		For	Against	Abstain	
3.	To consider and approve the investment projects financed by proceeds from the proposed A Share Offering and the relevant feasibility analysis;	131,100,356 (94.40%)	6,304,210 (4.54%)	1,466,907 (1.06%)	138,871,473
4.	To consider and approve the proposal for distribution of accumulated profits retained or plan for undertaking of unrecovered losses incurred cumulatively prior to the A Share Offering;	131,100,356 (94.40%)	6,304,210 (4.54%)	1,466,907 (1.06%)	138,871,473
5.	To consider and approve the plan for stabilizing A Share price within three years after the proposed A Share Offering as set out in Appendix I to the Circular;	131,100,356 (94.40%)	6,304,210 (4.54%)	1,466,907 (1.06%)	138,871,473
6.	To consider and approve the dilution of immediate return as a result of the A Share Offering and recovery measures;	131,100,356 (94.40%)	6,304,210 (4.54%)	1,466,907 (1.06%)	138,871,473
7.	To consider and approve the plan for dividend distribution to Shareholders in three years after the proposed A Share Offering as set out in Appendix II to the Circular;	101,677,100 (92.90%)	6,304,210 (5.76%)	1,466,907 (1.34%)	109,448,217
8.	To consider and approve the undertakings and restraining measures in respect of the proposed A Share Offering as set out in Appendix III to the Circular.	131,100,356 (94.40%)	6,304,210 (4.54%)	1,466,907 (1.06%)	138,871,473

As more than two-thirds of the votes from the H Shareholders (including their proxies) attending the Class Meeting of H Shareholders, with voting rights, were cast in favor of the resolutions above, these resolutions were duly passed.

### (III) Poll Results of the Class Meeting of Domestic Unlisted Shareholders

The poll results in respect of the resolutions proposed at the Class Meeting of Domestic Unlisted Shareholders were as follows:

Special Resolutions		Number of valid votes and percentage of total votes (%)			Total votes
		For	Against	Abstain	
1.	To consider and approve the proposed A Share Offering: (a) Place of listing; (b) Class of securities to be issued; (c) Nominal value of shares; (d) Target subscribers; (e) Schedule of the offering; (f) Method of offering; (g) Offering size; (h) Pricing methodology; (i) Implementation of strategic placing upon issue; (j) Method of underwriting; and (k) Validity period of resolutions in relation to the Offering.	253,625,563 (100.00%)	0 (0.00%)	0 (0.00%)	253,625,563
2.	To consider and approve the authorization to the Company's board and its authorized persons to deal with specific matters relating to the proposed A Share Offering with full discretion;	253,625,563 (100.00%)	0 (0.00%)	0 (0.00%)	253,625,563
3.	To consider and approve the investment projects financed by proceeds from the proposed A Share Offering and the relevant feasibility analysis;	253,625,563 (100.00%)	0 (0.00%)	0 (0.00%)	253,625,563
4.	To consider and approve the proposal for distribution of accumulated profits retained or plan for undertaking of unrecovered losses incurred cumulatively prior to the A Share Offering;	253,625,563 (100.00%)	0 (0.00%)	0 (0.00%)	253,625,563

Special Resolutions		Number of valid votes and percentage of total votes (%)			Total votes
		For	Against	Abstain	
5.	To consider and approve the plan for stabilizing A Share price within three years after the proposed A Share Offering as set out in Appendix I to the Circular;	253,625,563 (100.00%)	0 (0.00%)	0 (0.00%)	253,625,563
6.	To consider and approve the dilution of immediate return as a result of the A Share Offering and recovery measures;	253,625,563 (100.00%)	0 (0.00%)	0 (0.00%)	253,625,563
7.	To consider and approve the plan for dividend distribution to Shareholders in three years after the proposed A Share Offering as set out in Appendix II to the Circular;	253,625,563 (100.00%)	0 (0.00%)	0 (0.00%)	253,625,563
8.	To consider and approve the undertakings and restraining measures in respect of the proposed A Share Offering as set out in Appendix III to the Circular.	253,625,563 (100.00%)	0 (0.00%)	0 (0.00%)	253,625,563

As more than two-thirds of the votes from the Domestic Unlisted Shareholders (including their proxies) attending the Class Meeting of Domestic Unlisted Shareholders, with voting rights, were cast in favor of the resolutions above, these resolutions were duly passed.

## **CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN THE COMPOSITION OF BOARD COMMITTEE**

At the EGM, Dr. Cheng Hua (“**Dr. Cheng**”) was appointed as independent non-executive Director of the first session of the Board. The appointment of Dr. Cheng shall come into effect immediately after the conclusion of the EGM and until the expiry of the term of the first session of the Board (i.e. three years from October 30, 2020). For the biographical details of Dr. Cheng, please refer to the announcement of the Company dated November 16, 2022 and the circular dated November 21, 2022. As at the date of this announcement, there has been no change in the information disclosed in the aforesaid announcement and circular.

Ms. Gao Jian (“**Ms. Gao**”) ceased to be an independent non-executive Director, the chairman of the Audit Committee and a member of the Nomination Committee upon conclusion of the EGM. Ms. Gao has confirmed she has no disagreement with the Board and there are no other matters in relation to her resignation that needs to be brought to the attention of Shareholders or the Stock Exchange.

In place of Ms. Gao's positions as the chairman to the Audit Committee and a member to the Nomination Committee, with effect from the conclusion of the EGM, (i) Mr. Ho Kin Cheong Kelvin has been appointed as the chairman to the Audit Committee, (ii) Ms. Wang Chunfeng has been appointed as a member of the Audit Committee, and (iii) Dr. Cheng has been appointed as a member of the Nomination Committee.

The Board would like to express its sincere gratitude to Ms. Gao for her contributions to the Company during her tenure of office.

By order of the Board  
**MicroTech Medical (Hangzhou) Co., Ltd.**  
**Zheng Pan**  
*Chairman of the Board*

Hangzhou, the PRC, December 7, 2022

*As at the date of this announcement, the board of directors of the Company comprises Dr. Zheng Pan, Dr. Yu Fei, Dr. Shi Yonghui and Ms. Liu Xiu as executive Directors, Mr. Hu Xubo and Ms. Gao Yun as non-executive Directors, and Dr. Li Lihua, Ms. Wang Chunfeng, Mr. Ho Kin Cheong Kelvin and Dr. Cheng Hua as independent non-executive Directors.*